Legal and Regulatory Landscape for Peptides

What "Research Use Only" Means Legally

Nearly every peptide sold online carries a line such as "for research use only" or "not for human consumption." Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), a product is a drug if it's intended to treat or prevent disease, or to affect the structure or function of the body. A drug meant for people needs FDA approval before it can be sold. Chemicals sold to labs for experiments don't, so sellers use the research label to place their vials in that second group.

The weak point is the word "intended." FDA doesn't take intended use from the label alone. Under its intended-use regulation (21 CFR 201.128), it also weighs the seller's website and marketing, including what's sold alongside the vials. If that evidence points to human use, the disclaimer doesn't change what the product is. Community guides often call the research label a loophole, but in FDA's view it only holds when the rest of the business looks like laboratory supply.

Most research peptides aren't controlled substances, unlike anabolic steroids. So federal cases against peptide sellers run through the FD&C Act's rules on unapproved drugs rather than drug-scheduling law.

FDA Enforcement Against Research-Use Sellers in 2026

On March 31, 2026, FDA issued warning letters to two online sellers, Gram Peptides and Prime Sciences, over weight-loss peptides such as retatrutide and cagrilintide. A second batch dated August 24, 2026 went to four more sellers, including Peak Performance Peptides and Royal Peptides. Those letters mostly cover copies of approved drugs (listed below), and several also cite the bacteriostatic water sold with them.

The letters follow one line of reasoning. Each quotes the seller's "research use only" or "not for human consumption" statements, then says evidence from the website "establishes that your products are intended to be drugs for human use." FDA then classifies the products as unapproved new drugs under section 505(a) of the FD&C Act. Two details stand out:

• Much of the language FDA cited was cautious research phrasing. One letter quotes a tesamorelin page describing it as "studied for its role in stimulating endogenous growth hormone secretion."
• Selling bacteriostatic water counted as evidence, and so did a "peptide calculator" in the Royal Peptides and NuScience Peptides letters. FDA wrote that these provide "the means to prepare an injectable drug for human administration."

Most of the August products have approved US counterparts:

• Semaglutide (Ozempic and Wegovy)
• Tesamorelin (Egrifta)
• PT-141, or bremelanotide (Vyleesi)
• SS-31, or elamipretide (Forzinity, approved for Barth syndrome in September 2025)

That pattern is our inference; FDA hasn't said it is targeting copies of approved drugs.

Criminal cases are rarer. In July 2026, a federal judge sentenced Matthew Kawa, owner of Paradigm Peptides, to 70 months in prison after he pleaded guilty to selling unapproved drugs and illegally importing them. According to CBS News, his plea admitted the products were sold for human consumption despite the research label. Every 2026 action we found targets sellers, not buyers, though that describes enforcement so far and doesn't make buying lawful.

Other regulators take the same line. Australia's TGA said in April 2026 that a "research use only" disclaimer does not make supply lawful.

Compounding: The Regulated Middle Ground

Compounding pharmacies make customized drugs for individual patients with a prescription. Under section 503A of the FD&C Act, a pharmacy can compound from a bulk ingredient only if it has a USP or NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list. As of October 2026, most popular research peptides meet none of these conditions.

While nominated substances are under review, FDA sorts them into interim categories. Category 1 substances can be compounded under FDA's enforcement policy; Category 2 means FDA has identified "significant safety risks" and may act against compounders.

On April 15, 2026, FDA announced that 12 peptides would leave Category 2 because their nominators withdrew the nominations. The group includes BPC-157, TB-500 (the thymosin beta-4 fragment) and injectable GHK-Cu, and the removal took effect around April 22. Leaving Category 2 isn't permission to compound. These peptides now sit in no category and still aren't on the bulks list.

FDA's category list updated May 14, 2026 shows where other compounds stand:

• Category 2 still includes ibutamoren (MK-677) and kisspeptin-10.
• GHRP-2 and GHRP-6 are in Category 3.
• Non-injectable GHK-Cu went back into Category 1 after one nominator clarified it had withdrawn only the injectable nomination.
• Ipamorelin, which FDA's advisory committee reviewed in October 2024, doesn't appear in any 503A category, and no rule has added it to the bulks list.

On July 23-24, 2026, FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed seven of the withdrawn peptides. FDA staff recommended against all seven, but the committee voted to recommend six of them:

The votes are advice. FDA has to complete notice-and-comment rulemaking before any substance is added to the bulks list. As of October 2026, FDA hasn't issued a proposed rule or any interim policy on the six, according to compounding lawyers tracking the docket. A second PCAC meeting on the remaining withdrawn peptides, including GHK-Cu and melanotan II, is planned before the end of February 2027.

Sermorelin is the main exception among growth hormone peptides. It was approved as Geref for growth hormone deficiency in children, and its maker discontinued the product in 2008. In 2013 FDA determined Geref was not withdrawn for reasons of safety or effectiveness. Because sermorelin is a component of a formerly approved drug, pharmacies can compound it under 503A with a prescription, even though no approved sermorelin product is on the market.

Compounded GLP-1s and the 503B Proposal

Compounded semaglutide and tirzepatide spread while both drugs were in shortage. FDA declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage on February 21, 2025. FDA's current policy says a compounded product with the same active ingredient at a similar strength, such as semaglutide combined with vitamin B12, can still count as "essentially a copy" of an approved drug.

Outsourcing facilities registered under section 503B follow a separate bulks list. On April 30, 2026, FDA proposed excluding semaglutide and tirzepatide, along with liraglutide, from that list, finding "no clinical need" for outsourcing facilities to compound them from bulk ingredients. As of early October 2026, we found no final decision.

Prescription Medicines vs. Research Vials

Tesamorelin is FDA-approved as Egrifta, a prescription medicine, to reduce excess abdominal fat in adults with HIV-associated lipodystrophy; the Egrifta WR formulation was approved in March 2025. Its label states it is "not indicated for weight loss management." Semaglutide is sold by prescription as Ozempic and Wegovy. A vial labeled "tesamorelin" or "semaglutide" from a research seller isn't one of those medicines. It hasn't been made or tested under an FDA approval, and FDA's August letters call such products unapproved new drugs.

It helps to think of peptide legality in three tiers.

The research tier has no FDA oversight of identity or purity. Vendor certificates of analysis are the main assurance, and Kawa admitted Paradigm forged its lab certificates, according to CBS News. For the evidence behind individual compounds, which ranges from approved medicines to rodent studies alone, see how the evidence differs across peptides.

How WADA Rules Differ From the Law

The World Anti-Doping Agency (WADA) Prohibited List is a sport rule, not a law. It binds athletes in sports covered by the World Anti-Doping Code, and breaking it brings a sporting sanction, not a criminal charge. WADA's 2026 list names BPC-157 in S0 and TB-500 in S2.3, and it bans growth hormone releasers such as tesamorelin and ipamorelin under S2.2.4, all at all times. A prescription alone doesn't change that. Professional leagues can run their own programs; the UFC's, for example, has been administered by Combat Sports Anti-Doping (CSAD) since 2024. For how substances get onto the list, see the WADA criteria for banning peptides.

What to Watch Next

• Whether FDA proposes a rule adding any of the six PCAC-recommended peptides to the 503A bulks list, or chooses an interim policy instead.
• The second PCAC meeting, planned before the end of February 2027.
• FDA's final decision on the 503B GLP-1 proposal.